KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells $61,890.75 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Nicole Sweeny sold 3,975 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $61,890.75. Following the transaction, the insider directly owned 47,003 shares in the company, valued at $731,836.71. This represents a 7.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

KalVista Pharmaceuticals Price Performance

KalVista Pharmaceuticals stock traded up $0.21 during midday trading on Tuesday, reaching $15.77. The company’s stock had a trading volume of 751,567 shares, compared to its average volume of 635,299. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $9.23 and a fifty-two week high of $19.00. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. The stock’s 50 day simple moving average is $15.47 and its 200 day simple moving average is $13.94. The firm has a market capitalization of $797.17 million, a PE ratio of -3.99 and a beta of -0.19.

Wall Street Analyst Weigh In

A number of research firms recently commented on KALV. Citizens Jmp decreased their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Tuesday, November 11th. Citigroup reaffirmed a “market outperform” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. Wall Street Zen upgraded KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Finally, Needham & Company LLC raised their price objective on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $29.40.

Institutional Trading of KalVista Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Emerald Advisers LLC grew its position in shares of KalVista Pharmaceuticals by 30.2% in the third quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock valued at $16,458,000 after purchasing an additional 313,205 shares during the last quarter. Emerald Mutual Fund Advisers Trust lifted its stake in KalVista Pharmaceuticals by 26.4% in the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 768,972 shares of the specialty pharmaceutical company’s stock valued at $8,693,000 after buying an additional 160,759 shares in the last quarter. Stonepine Capital Management LLC lifted its stake in KalVista Pharmaceuticals by 364.0% in the 2nd quarter. Stonepine Capital Management LLC now owns 100,000 shares of the specialty pharmaceutical company’s stock valued at $1,130,000 after buying an additional 78,450 shares in the last quarter. F m Investments LLC grew its holdings in KalVista Pharmaceuticals by 263.8% during the 2nd quarter. F m Investments LLC now owns 182,262 shares of the specialty pharmaceutical company’s stock valued at $2,060,000 after buying an additional 132,165 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ increased its position in KalVista Pharmaceuticals by 391.9% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 200,991 shares of the specialty pharmaceutical company’s stock worth $2,449,000 after buying an additional 160,128 shares in the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.